Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer.

MLA

Kim, Rim S., et al. “Stromal Tumor-Infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer.” JNCI: Journal of the National Cancer Institute, vol. 111, no. 8, Aug. 2019, pp. 867–71. EBSCOhost, https://doi.org/10.1093/jnci/djz032.

APA

Kim, R. S., Song, N., Gavin, P. G., Salgado, R., Bandos, H., Kos, Z., Floris, G., Eynden, G. G. G. M. V. den, Badve, S., Demaria, S., Rastogi, P., Fehrenbacher, L., Mamounas, E. P., Swain, S. M., Wickerham, D. L., Costantino, J. P., Paik, S., Wolmark, N., Geyer, C. E., & Lucas, P. C. (2019). Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer. JNCI: Journal of the National Cancer Institute, 111(8), 867–871. https://doi.org/10.1093/jnci/djz032

Chicago

Kim, Rim S, Nan Song, Patrick G Gavin, Roberto Salgado, Hanna Bandos, Zuzana Kos, Giuseppe Floris, et al. 2019. “Stromal Tumor-Infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer.” JNCI: Journal of the National Cancer Institute 111 (8): 867–71. doi:10.1093/jnci/djz032.